CAMBIO DE DISCURSO : LA SECOND-LINE SCLC-ES TRAS EL FIASCO DE LA FASE III LAGOON YA MEJOR NI NOMBRARLA...CAMBIAMOS DISCURSO A MANTENIMIENTO EN FIRTS-LINE Y PASAMOS DEL VIAL DE 4 Mg AI VIAL DE 2 Mg .//. JazzPharma TO WITHDRAW LURBINECTEDIN WITH US_FDA IN SECOND-LINE SCLC-ES...EN ESPAÑA NO SE HAN ENTERADO AÚN...SI NO EXISTIERA IMFORTE...AHORA MISMO PHARMAMAR ESTARÍA ANTE UNA GRAVE SITUACIÓN ... 2 DE OCTUBRE DE 2028 ... ES LA FECHA MÁS TEPMPRANA PARA LA POSIBLE ENTRADA DE GENÉRICOS .
27 junio 2007
26 junio 2007
Pharma Mar consigue la Patente de una Nueva Familia de AntiCancerigenos derivados de la Esponga Theonella Swinhoei .
ANTITUMOUR COMPOUNDS .
Publication number: WO2007068776
Publication date: 2007-06-21
Inventor: MARTIN LOPEZ MA JESUS (ES); REYES BENITEZ JOSE FERNANDO (ES); FERNANDEZ RODRIGUEZ ROGELIO (ES); FRANCESCH SOLLOSO ANDRES (ES); CUEVAS MARCHANTE MARIA DEL CAR (ES); COELLO MOLINERO LAURA (ES)
Applicant: PHARMA MAR SA (ES); MARTIN LOPEZ MA JESUS (ES); REYES BENITEZ JOSE FERNANDO (ES); FERNANDEZ RODRIGUEZ ROGELIO (ES); FRANCESCH SOLLOSO ANDRES (ES); CUEVAS MARCHANTE MARIA DEL CAR (ES); COELLO MOLINERO LAURA
(ES) Classification: - international: C07D493/18; A61K31/357; A61P35/00; C07D311/00; C07D323/00; C07D493/22; C07D493/00; A61K31/357; A61P35/00; C07D311/00; C07D323/00; - European: Application number: WO2006ES00687 20061214 Priority number(s): ES20050003092 20051215
Abstract of WO2007068776 The invention relates to novel antitumour compounds having general formula (I) and to the corresponding pharmaceutically-acceptable salts, derivatives, pro-drugs and stereoisomers thereof. The inventive compounds can be obtained by isolating a sponge from family Theonellidae, genus Theonella and species swinhoei, and forming derivatives from the isolated compounds. Said compounds have a cytotoxic activity and can be used for the treatment of cancer.
Abstract of WO2007068776 The invention relates to novel antitumour compounds having general formula (I) and to the corresponding pharmaceutically-acceptable salts, derivatives, pro-drugs and stereoisomers thereof. The inventive compounds can be obtained by isolating a sponge from family Theonellidae, genus Theonella and species swinhoei, and forming derivatives from the isolated compounds. Said compounds have a cytotoxic activity and can be used for the treatment of cancer.
25 junio 2007
New cytotoxic diterpenylnaphthohydroquinone derivatives obtained from a natural diterpenoid.
Junio 2007 .
New cytotoxic diterpenylnaphthohydroquinone derivatives obtained from a natural diterpenoid.
Miguel Del Corral JM, Castro MA, Lucena Rodrı Guez M, Chamorro P, Cuevas C, San Feliciano A
Departamento de Quı´mica Farmacéutica, Facultad de Farmacia, Universidad de Salamanca, E-37007 Salamanca, Spain.
Diterpenylquinone/hydroquinone derivatives were prepared through Diels-Alder cycloaddition between natural myrcecommunic acid or its methyl ester and p-benzoquinone (p-BQ), using BF(3).Et(2)O as catalyst or under microwave (Mw) irradiation. Acetyl, methyl and benzyl derivatives of several diterpenylnaphthohydroquinone were prepared from cycloadducts following two basic synthetic strategies, either protection before aromatisation or viceversa. Some of them were further functionalised at the B-ring of the decaline core. Most of the new compounds were evaluated and some of them resulted cytotoxic against several tumour cell lines with IC(50) values under the muM level.
New cytotoxic diterpenylnaphthohydroquinone derivatives obtained from a natural diterpenoid.
Miguel Del Corral JM, Castro MA, Lucena Rodrı Guez M, Chamorro P, Cuevas C, San Feliciano A
Departamento de Quı´mica Farmacéutica, Facultad de Farmacia, Universidad de Salamanca, E-37007 Salamanca, Spain.
Diterpenylquinone/hydroquinone derivatives were prepared through Diels-Alder cycloaddition between natural myrcecommunic acid or its methyl ester and p-benzoquinone (p-BQ), using BF(3).Et(2)O as catalyst or under microwave (Mw) irradiation. Acetyl, methyl and benzyl derivatives of several diterpenylnaphthohydroquinone were prepared from cycloadducts following two basic synthetic strategies, either protection before aromatisation or viceversa. Some of them were further functionalised at the B-ring of the decaline core. Most of the new compounds were evaluated and some of them resulted cytotoxic against several tumour cell lines with IC(50) values under the muM level.
23 junio 2007
22 junio 2007
21 junio 2007
NeuroPharma Patente : Dibenzene derivatives as calcium channel blockers .
Dibenzene derivatives as calcium channel blockers
Publication number: EP1798220 Publication date: 2007-06-20 Inventor: MARTINEZ GIL ANA (ES); CASTRO MORERA ANA (ES); MEDINA PADILLA MIGUEL (ES); MUNOZ RUIZ PILAR (ES); RUBIO ARRIETA LAURA (ES); GARCIA PALOMERO ESTHER (ES); DE AUSTRIA CELIA (ES) Applicant: NEUROPHARMA S A (ES) Classification: - international: C07C255/60; A61K31/166; A61P25/28; C07C255/00; A61K31/166; A61P25/00; - European: Application number: EP20050077910 20051216 Priority number(s): EP20050077910 20051216
Abstract of EP1798220 The invention is directed to a compound of formula (I) Having VDCC blocking activity. These compounds are useful for the treatment of a series of human diseases and conditions, especially cognitive or neurodegenerative diseases or conditions.
Publication number: EP1798220 Publication date: 2007-06-20 Inventor: MARTINEZ GIL ANA (ES); CASTRO MORERA ANA (ES); MEDINA PADILLA MIGUEL (ES); MUNOZ RUIZ PILAR (ES); RUBIO ARRIETA LAURA (ES); GARCIA PALOMERO ESTHER (ES); DE AUSTRIA CELIA (ES) Applicant: NEUROPHARMA S A (ES) Classification: - international: C07C255/60; A61K31/166; A61P25/28; C07C255/00; A61K31/166; A61P25/00; - European: Application number: EP20050077910 20051216 Priority number(s): EP20050077910 20051216
Abstract of EP1798220 The invention is directed to a compound of formula (I) Having VDCC blocking activity. These compounds are useful for the treatment of a series of human diseases and conditions, especially cognitive or neurodegenerative diseases or conditions.
ANTITUMORAL ANALOGS OF ET-743, PHARMACEUTICAL COMPOSITION BASED THEREON AND USE THEREOF .
ANTITUMORAL ANALOGS OF ET-743, PHARMACEUTICAL COMPOSITION BASED THEREON AND USE THEREOF .
Publication number: UA78680 Publication date: 2007-04-25 Inventor: MARTIN MARIA JESUS (ES) Applicant: PHARMA MAR SA (ES) Classification: - international: A61K31/499; A61P31/04; A61P35/00; C07D471/18; C07D471/22; C07D487/18; C07D491/22; C07D515/00; A61K31/499; A61P31/00; A61P35/00; C07D471/00; C07D487/00; C07D491/00; C07D515/00; - European: Application number: UA20021210092 20010515 Priority number(s): WO2000GB01852 20000515; WO2001GB02110 20010515
Abstract of UA78680 Antitumour compounds have the five membered fused ring ecleinascidin structure of the formula (XIV). The present compounds lack a 1,4-bridging group as found in the ecteinascidins. They have at the C-1 position a substituent selected from an optionally protected or derivatised aminomethylene group or an optionally protected or derivatised hydroxymethylene group. , (XIV)
Publication number: UA78680 Publication date: 2007-04-25 Inventor: MARTIN MARIA JESUS (ES) Applicant: PHARMA MAR SA (ES) Classification: - international: A61K31/499; A61P31/04; A61P35/00; C07D471/18; C07D471/22; C07D487/18; C07D491/22; C07D515/00; A61K31/499; A61P31/00; A61P35/00; C07D471/00; C07D487/00; C07D491/00; C07D515/00; - European: Application number: UA20021210092 20010515 Priority number(s): WO2000GB01852 20000515; WO2001GB02110 20010515
Abstract of UA78680 Antitumour compounds have the five membered fused ring ecleinascidin structure of the formula (XIV). The present compounds lack a 1,4-bridging group as found in the ecteinascidins. They have at the C-1 position a substituent selected from an optionally protected or derivatised aminomethylene group or an optionally protected or derivatised hydroxymethylene group. , (XIV)
19 junio 2007
Suscribirse a:
Entradas (Atom)